【4月文獻戰報】Bioss抗體新增高分文獻精彩呈現-商家動態-資訊-生物在線

【4月文獻戰報】Bioss抗體新增高分文獻精彩呈現

作者：北京博奧森生物技術有限公司 2023-06-21T09:37 (訪問量:12981)


截止目前，引用Bioss產品發表的文獻共24858篇，總影響因子116841.414分，發表在Nature, Science, Cell以及Immunity等頂級期刊的文獻共58篇，合作單位覆蓋了清華、北大、復旦、華盛頓大學、麻省理工學院、東京大學以及紐約大學等國際知名研究機構上百所。

我們每月收集引用Bioss產品發表的文獻。若您在當月已發表SCI文章，但未被我公司收集，請致電Bioss，我們將贈予現金鼓勵，金額標準請參考“發文章 領獎金”活動頁面。

近期收錄2023年4月引用Bioss產品發表的文獻共288篇（圖一，綠色柱），文章影響因子(IF) 總和高達2009.871，其中，10分以上文獻47篇（圖二）。

圖一

圖二



本文主要分享引用Bioss產品發表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的5篇 IF＞15 的文獻摘要，讓我們一起欣賞吧。


Cell Discovery [IF=38.079]



文獻引用抗體：bsm-41516M

Mouse Anti- SARS-CoV-2 (2019-nCoV) Spike RBD mAb | WB

作者單位：北京大學未來技術學院生物醫學工程系

摘要：Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has elicited a worldwide pandemic since late 2019. There has been ~675 million confirmed coronavirus disease 2019 (COVID-19) cases, leading to more than 6.8 million deaths as of March 1, 2023. Five SARS-CoV-2 variants of concern (VOCs) were tracked as they emerged and were subsequently characterized. However, it is still difficult to predict the next dominant variant due to the rapid evolution of its spike (S) glycoprotein, which affects the binding activity between cellular receptor angiotensin-converting enzyme 2 (ACE2) and blocks the presenting epitope from humoral monoclonal antibody (mAb) recognition. Here, we established a robust mammalian cell-surface-display platform to study the interactions of S-ACE2 and S-mAb on a large scale. A lentivirus library of S variants was generated via in silico chip synthesis followed by site-directed saturation mutagenesis, after which the enriched candidates were acquired through single-cell fluorescence sorting and analyzed by third-generation DNA sequencing technologies. The mutational landscape provides a blueprint for understanding the key residues of the S protein binding affinity to ACE2 and mAb evasion. It was found that S205F, Y453F, Q493A, Q493M, Q498H, Q498Y, N501F, and N501T showed a 3–12-fold increase in infectivity, of which Y453F, Q493A, and Q498Y exhibited at least a 10-fold resistance to mAbs REGN10933, LY-CoV555, and REGN10987, respectively. These methods for mammalian cells may assist in the precise control of SARS-CoV-2 in the future.

JOURNAL OF HEPATOLOGY

[IF=30.083]


文獻引用抗體：bs-1278R

Anti-8-OHdG (DNA/RNA Damage) pAb | IHC

作者單位：美國明尼蘇達州羅切斯特市梅奧診所生物化學和分子生物學部

摘要：Background & Aims

The prevalence of non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is rising rapidly, yet its underlying mechanisms remain unclear. Herein, we aim to determine the role of hypoxia-inducible lipid droplet associated protein (HILPDA)/hypoxia-inducible gene 2 (HIG2), a selective inhibitor of intracellular lipolysis, in NASH-driven HCC.

Methods

The clinical significance of HILPDA was assessed in human NASH-driven HCC specimens by immunohistochemistry and transcriptomics analyses. The oncogenic effect of HILPDA was assessed in human HCC cells and in 3D epithelial spheroids upon exposure to free fatty acids and either normoxia or hypoxia. Lipidomics profiling of wild-type and HILPDA knockout HCC cells was assessed via shotgun and targeted approaches. Wild-type (Hilpdafl/fl) and hepatocyte-specific Hilpda knockout

北京博奧森生物技術有限公司 商家主頁

地 址： 北京市通州區馬駒橋鎮聯東U谷西區四期67號樓

聯系人： 秦

電 話： 4009019800

傳 真： 010-58129612

Email：sales@bioss.com.cn

相關咨詢

凋亡、焦亡、鐵死亡......細胞死法那么多，選對標記物才是關鍵 (暫無發布時間 瀏覽數:11698)

經典細胞類型標志物匯總，精準識別不踩坑 (暫無發布時間 瀏覽數:12354)

精選細胞器標志物抗體，助您“點亮”細胞器 (暫無發布時間 瀏覽數:10057)

展會邀請 | 博奧森參展CSCB 2026 聚焦細胞生物學前沿，共話科研新突破 (暫無發布時間 瀏覽數:12178)

腫瘤轉移研究必備：EMT關鍵標志物抗體選擇指南 (暫無發布時間 瀏覽數:12216)

展會回顧 | 春風有信，鷺島相約，博奧森CACLP之旅圓滿落幕 (暫無發布時間 瀏覽數:13012)

博奧森星推薦 | FOXP3 抗體 (暫無發布時間 瀏覽數:11979)

博奧森星推薦 | PD-1 抗體 (暫無發布時間 瀏覽數:12571)

博奧森星推薦 | PD-L1 抗體 (暫無發布時間 瀏覽數:12781)

【26年1月文獻戰報】博奧森高分文獻精彩呈現 (暫無發布時間 瀏覽數:12293)

ADVERTISEMENT